Innovotech Inc (IOT) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.039x

Based on the latest financial reports, Innovotech Inc (IOT) has a cash flow conversion efficiency ratio of 0.039x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$140.68K ≈ $101.76K USD) by net assets (CA$3.65 Million ≈ $2.64 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Innovotech Inc - Cash Flow Conversion Efficiency Trend (2003–2025)

This chart illustrates how Innovotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Innovotech Inc for a breakdown of total debt and financial obligations.

Innovotech Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Innovotech Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Soco Corporation Ltd
AU:SOC
-0.288x
Noroo Holdings Co Ltd
KO:000325
0.010x
Nexgel Inc
NASDAQ:NXGL
0.057x
Trio Petroleum Corp.
NYSE MKT:TPET
-0.060x
KST Beteiligungs AG
F:KSW
N/A
Enlitic Inc
AU:ENL
-0.698x
Nutritional Growth Solutions Ltd
AU:NGS
-2.363x
Archidply Decor Limited
NSE:ADL
0.012x

Annual Cash Flow Conversion Efficiency for Innovotech Inc (2003–2025)

The table below shows the annual cash flow conversion efficiency of Innovotech Inc from 2003 to 2025. For the full company profile with market capitalisation and key ratios, see Innovotech Inc (IOT) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 CA$3.65 Million
≈ $2.64 Million
CA$-62.35K
≈ $-45.11K
-0.017x +45.09%
2024-12-31 CA$2.62 Million
≈ $1.90 Million
CA$-81.64K
≈ $-59.06K
-0.031x +86.37%
2023-12-31 CA$998.60K
≈ $722.37K
CA$-228.08K
≈ $-164.99K
-0.228x -215.91%
2022-12-31 CA$1.06 Million
≈ $764.99K
CA$208.39K
≈ $150.75K
0.197x +826.07%
2021-12-31 CA$1.18 Million
≈ $851.37K
CA$25.04K
≈ $18.12K
0.021x -92.17%
2020-12-31 CA$644.98K
≈ $466.57K
CA$175.24K
≈ $126.76K
0.272x -65.07%
2019-12-31 CA$98.09K
≈ $70.95K
CA$76.30K
≈ $55.19K
0.778x +125.90%
2018-12-31 CA$93.47K
≈ $67.61K
CA$-280.75K
≈ $-203.09K
-3.004x -243.54%
2017-12-31 CA$181.51K
≈ $131.30K
CA$-158.69K
≈ $-114.80K
-0.874x -45878.85%
2016-12-31 CA$-1.22 Million
≈ $-881.43K
CA$2.32K
≈ $1.68K
-0.002x +95.34%
2015-12-31 CA$-1.00 Million
≈ $-725.51K
CA$40.90K
≈ $29.58K
-0.041x -135.58%
2014-12-31 CA$-765.66K
≈ $-553.87K
CA$-87.75K
≈ $-63.48K
0.115x -88.37%
2013-12-31 CA$-569.33K
≈ $-411.85K
CA$-560.96K
≈ $-405.79K
0.985x +6432.59%
2003-12-31 CA$836.94K
≈ $605.43K
CA$-13.02K
≈ $-9.42K
-0.016x -171.08%
2003-09-30 CA$841.40K
≈ $608.65K
CA$18.42K
≈ $13.32K
0.022x --

About Innovotech Inc

V:IOT Canada Biotechnology
Market Cap
$4.73 Million
CA$6.53 Million CAD
Market Cap Rank
#28615 Global
#1309 in Canada
Share Price
CA$0.12
Change (1 day)
+0.00%
52-Week Range
CA$0.12 - CA$0.34
All Time High
CA$0.34
About

Innovotech Inc. provides assay kits used in growing microbial biofilms for research purposes in Canada, the United States, and internationally. The company offers InnovoSIL, a silver periodate antimicrobial compounds for medical applications; and MBEC Assay kit, a screening assay used to determine the efficacy of antimicrobials against biofilms of a variety of microorganisms; pre-coated MBEC Assa… Read more